Jazz Pharmaceuticals Submitted Luvox CR, Luvox For FDA Approval
FDA has accepted for review the submission of the complete response by Jazz Pharmaceuticals for Luvox CR (fluvoxamine maleate) extended-release capsules.
The PDUFA action date is December 22, 2007.
The NDA for Luvox CR seeks marketing approval for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) and for the treatment of social anxiety disorder (SAD). Luvox CR is an extended-release formulation of fluvoxamine maleate, a selective serotonin reuptake inhibitor.
The FDA has also accepted the submission of the complete response by Solvay Pharmaceuticals to the FDA approvable letter for Luvox (fluvoxamine maleate) immediate release tablets. The PDUFA action date is December 21, 2007.
In January 2007, Jazz Pharmaceuticals licensed from Solvay Pharmaceuticals the right to market Luvox CR and Luvox in the United States. Solvay Pharmaceuticals retains the right to market both products in other territories around the world. Subject to receipt of FDA approval, Jazz Pharmaceuticals expects to launch Luvox CR in the United States during the first quarter of 2008.
Obsessive compulsive disorder (OCD) is a chronic anxiety disorder characterized by persistent, unwanted thoughts, or obsessions, and repetitive behaviors or rituals, or compulsions. According to the National Institute of Mental Health (NIMH), OCD affects approximately 2.2 million adults in the United States. It is estimated that 60% of patients with OCD worldwide receive no treatment for their disorder. Patients with OCD use rituals to help control anxiety related to their obsessive thoughts, and these rituals become disruptive to their daily life. While these patients often realize that their obsessions and compulsions are irrational or excessive, they frequently have little or no control over them. Rituals adopted by OCD patients may provide them with transient relief from anxiety, but the rituals do not provide sustained comfort. Frequently, the rituals become so overwhelming that patients are unable to function normally in their daily lives.
Social anxiety disorder (SAD) is characterized by the fear and avoidance of social or performance situations where patients feel that others may scrutinize them and they may embarrass themselves. According to the NIMH, SAD affects approximately 15 million adults in the United States. Despite the prevalence of the disorder, SAD remains underdiagnosed and undertreated by clinicians. SAD patients have anticipatory anxiety about these situations, and this anxiety can become so pronounced that patients cannot function normally in their daily lives. Social anxieties can be limited to a particular situation or apply to a variety of situations. In addition to anxiety, patients experience physical symptoms including blushing, sweating, trembling, and nausea.